{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tb-500-tirzepatide","title":"TB-500 and Tirzepatide: Layered Repair Pathways and Metabolic Load Evidence","body":"## What's breaking down\n\nNo single disease profile defines this cross. The slug points to someone already using Tirzepatide for metabolic control and weight change who is also exploring TB-500 for tissue repair questions. Degeneration layers that commonly appear in such discussions include stalled inflammation clearance after micro-injury, disorganized repair-cell migration to damage sites, and ongoing mechanical stress from higher body weight on spine and joints. Repair outruns degeneration when cells reach the site, clear debris, and rebuild matrix. When migration stalls or load stays high, the imbalance persists.\n\n## Why TB-500 might help you\n\n1. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n2. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n3. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\n2. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\n3. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- TB-500 → inflammation clearance / repair-cell migration\n- Tirzepatide → metabolic load / body weight\n\n## What the evidence actually shows\n\nHuman data on full-length thymosin beta-4 (TB4) includes small trials for cardiac repair after heart attack and for eye surface healing. One 2016 pilot in STEMI patients suggested feasibility and safety for TB4-optimized cell therapy. Separate eye trials showed reduced dryness and discomfort. Wound healing trials reported faster closure in certain chronic ulcers. TB-500 itself, the fragment, lacks dedicated large human trials; most support remains preclinical or mechanistic.\n\nTirzepatide human trials (SURMOUNT series) show 15-21% average body weight reduction over 72 weeks in obesity cohorts. Weight loss of this magnitude reduces compressive force on lumbar discs and joints. Tirzepatide data is human and large-scale.\n\nPreclinical work on TB4/TB-500 centers on actin sequestration, angiogenesis, and reduced fibrosis in rat and mouse injury models. Rat wound and cardiac studies demonstrate cell migration and matrix remodeling. No large human randomized controlled trials exist for TB-500 specifically.\n\nAnecdotal reports on forums describe users pairing TB-500 with recovery goals while on GLP-1 agents, but these remain individual accounts without controlled measurement.\n\n## What scientists say\n\nReviews note TB4's role in embryonic-like repair programs in adult tissues, with early human signals in heart and eye but call for more controlled data. Tirzepatide researchers emphasize sustained weight reduction and metabolic improvement in published trial results. No peer-reviewed papers directly examine the TB-500 plus Tirzepatide pairing.\n\n## What people say on Reddit\n\nForum threads mention TB-500 alongside recovery stacks and occasionally list Tirzepatide in broader peptide regimens for long-term users. Discussions focus on perceived tissue support during weight change rather than combined mechanisms. Logs are personal and vary in detail.\n\n## What people say on X\n\nPosts referencing both compounds are sparse and mostly promotional or speculative. Few verified user reports tie specific outcomes to the combination.\n\n## What we do not know\n\nNo human trials test TB-500 during Tirzepatide treatment. Long-term effects on joint loading after major weight loss combined with repair peptides remain unstudied. Individual responses to either compound vary widely.\n\n## Safety and limits\n\nTirzepatide carries documented gastrointestinal side effects in trials. TB-500 and TB4 show favorable short-term safety signals in the limited human data available, yet regulatory status for research peptides limits clinical oversight. Evidence grading stays separate: human trial data for Tirzepatide weight effects, smaller human signals plus mostly preclinical for TB4/TB-500, and anecdotal for stacks.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tb-500-tirzepatide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Human trials of full-length TB4 showed reduced eye dryness and faster wound closure in small studies.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Separates human data from preclinical for TB-500 discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Tirzepatide produced 15-21% mean weight loss over 72 weeks in SURMOUNT obesity trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides quantified human metabolic load reduction data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"TB-500 fragment lacks large dedicated human trials; support is mainly preclinical.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Maintains evidence tier separation.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users discuss TB-500 in recovery stacks sometimes listed with Tirzepatide.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents forum-level reports without claiming efficacy.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://www.innerbody.com/thymosin-beta-4-and-tb-500","title":"TB4 and TB-500 Peptide Therapy | What to Know in 2026","quote":"A 2021 review covers the results of a few human TB4 trials... eye health... wound healing both resulted in the peptide accelerating the healing process.","summary":"Summarizes limited human TB4 trial signals in eye and wound contexts.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:29:03.186Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"bf21d43aaf96337a9138ad74f5402b928b16e118dd3ae5f73e447b695a7d42d5"},{"id":"s2","type":"clinical_trial","url":"https://www.prnewswire.com/news-releases/tirzepatide-demonstrated-significant-and-superior-weight-loss-compared-to-placebo-in-two-pivotal-studies-301887287.html","title":"Tirzepatide demonstrated significant and superior weight loss","quote":"Participants in SURMOUNT-3... additional 21.1% mean weight loss","summary":"Reports quantified weight loss from pivotal human trials.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:29:03.186Z","link_status":"ok","quote_status":"unverified","prev":"bf21d43aaf96337a9138ad74f5402b928b16e118dd3ae5f73e447b695a7d42d5","hash":"40a66d44e5efba6bfa83fd1a25008220cbb9a9f8f5c647e8b84bfcfe597eb6e1"},{"id":"s3","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing","quote":"We conducted a scoping review to map the evidence on TB4 and TB-500 in tissue healing, regeneration, and musculoskeletal repair.","summary":"Highlights predominantly preclinical evidence base.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:29:03.186Z","link_status":"http_403","quote_status":"unverified","prev":"40a66d44e5efba6bfa83fd1a25008220cbb9a9f8f5c647e8b84bfcfe597eb6e1","hash":"2c2d152f2124fe3314e4713ac4f6396ef2b181f98c89d0abe958a6182fe8815b"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/NTNPerformance/comments/1tc5a9d/peptide_stacking_cheat_sheet_what_goes_together/","title":"Peptide stacking cheat sheet","quote":"BPC-157 + TB-500 The wolverine stack... Tirzepatide + CJC/Ipamorelin","summary":"Captures forum discussion of peptide combinations including Tirzepatide context.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:29:03.186Z","link_status":"ok","quote_status":"unverified","prev":"2c2d152f2124fe3314e4713ac4f6396ef2b181f98c89d0abe958a6182fe8815b","hash":"3ed56389b2b16c31af8a53188a083addd46c7c258beb674a366d6778ed2f3934"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:29:03.788Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"TB-500 and Tirzepatide: Layered Repair Pathways and Metabolic Load Evidence","register":"source_ledger","body":"## What's breaking down\n\nNo single disease profile defines this cross. The slug points to someone already using Tirzepatide for metabolic control and weight change who is also exploring TB-500 for tissue repair questions. Degeneration layers that commonly appear in such discussions include stalled inflammation clearance after micro-injury, disorganized repair-cell migration to damage sites, and ongoing mechanical stress from higher body weight on spine and joints. Repair outruns degeneration when cells reach the site, clear debris, and rebuild matrix. When migration stalls or load stays high, the imbalance persists.\n\n## Why TB-500 might help you\n\n1. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n2. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n3. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\n2. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\n3. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- TB-500 → inflammation clearance / repair-cell migration\n- Tirzepatide → metabolic load / body weight\n\n## What the evidence actually shows\n\nHuman data on full-length thymosin beta-4 (TB4) includes small trials for cardiac repair after heart attack and for eye surface healing. One 2016 pilot in STEMI patients suggested feasibility and safety for TB4-optimized cell therapy. Separate eye trials showed reduced dryness and discomfort. Wound healing trials reported faster closure in certain chronic ulcers. TB-500 itself, the fragment, lacks dedicated large human trials; most support remains preclinical or mechanistic.\n\nTirzepatide human trials (SURMOUNT series) show 15-21% average body weight reduction over 72 weeks in obesity cohorts. Weight loss of this magnitude reduces compressive force on lumbar discs and joints. Tirzepatide data is human and large-scale.\n\nPreclinical work on TB4/TB-500 centers on actin sequestration, angiogenesis, and reduced fibrosis in rat and mouse injury models. Rat wound and cardiac studies demonstrate cell migration and matrix remodeling. No large human randomized controlled trials exist for TB-500 specifically.\n\nAnecdotal reports on forums describe users pairing TB-500 with recovery goals while on GLP-1 agents, but these remain individual accounts without controlled measurement.\n\n## What scientists say\n\nReviews note TB4's role in embryonic-like repair programs in adult tissues, with early human signals in heart and eye but call for more controlled data. Tirzepatide researchers emphasize sustained weight reduction and metabolic improvement in published trial results. No peer-reviewed papers directly examine the TB-500 plus Tirzepatide pairing.\n\n## What people say on Reddit\n\nForum threads mention TB-500 alongside recovery stacks and occasionally list Tirzepatide in broader peptide regimens for long-term users. Discussions focus on perceived tissue support during weight change rather than combined mechanisms. Logs are personal and vary in detail.\n\n## What people say on X\n\nPosts referencing both compounds are sparse and mostly promotional or speculative. Few verified user reports tie specific outcomes to the combination.\n\n## What we do not know\n\nNo human trials test TB-500 during Tirzepatide treatment. Long-term effects on joint loading after major weight loss combined with repair peptides remain unstudied. Individual responses to either compound vary widely.\n\n## Safety and limits\n\nTirzepatide carries documented gastrointestinal side effects in trials. TB-500 and TB4 show favorable short-term safety signals in the limited human data available, yet regulatory status for research peptides limits clinical oversight. Evidence grading stays separate: human trial data for Tirzepatide weight effects, smaller human signals plus mostly preclinical for TB4/TB-500, and anecdotal for stacks.","claims":[{"id":"c1","text":"Human trials of full-length TB4 showed reduced eye dryness and faster wound closure in small studies.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Separates human data from preclinical for TB-500 discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Tirzepatide produced 15-21% mean weight loss over 72 weeks in SURMOUNT obesity trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides quantified human metabolic load reduction data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"TB-500 fragment lacks large dedicated human trials; support is mainly preclinical.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Maintains evidence tier separation.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users discuss TB-500 in recovery stacks sometimes listed with Tirzepatide.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents forum-level reports without claiming efficacy.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://www.innerbody.com/thymosin-beta-4-and-tb-500","title":"TB4 and TB-500 Peptide Therapy | What to Know in 2026","quote":"A 2021 review covers the results of a few human TB4 trials... eye health... wound healing both resulted in the peptide accelerating the healing process.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"clinical_trial","url":"https://www.prnewswire.com/news-releases/tirzepatide-demonstrated-significant-and-superior-weight-loss-compared-to-placebo-in-two-pivotal-studies-301887287.html","title":"Tirzepatide demonstrated significant and superior weight loss","quote":"Participants in SURMOUNT-3... additional 21.1% mean weight loss","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing","quote":"We conducted a scoping review to map the evidence on TB4 and TB-500 in tissue healing, regeneration, and musculoskeletal repair.","link_status":"http_403","quote_status":"unverified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/NTNPerformance/comments/1tc5a9d/peptide_stacking_cheat_sheet_what_goes_together/","title":"Peptide stacking cheat sheet","quote":"BPC-157 + TB-500 The wolverine stack... Tirzepatide + CJC/Ipamorelin","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":15403,"tokens_out":3018,"cost":0.02679875,"prev_hash":"genesis","hash":"81a855ee4fb84d77b63987384a745b4535db3c6bf6002a5467174bdb1f2e60e3"}],"provenance":[{"ts":"2026-06-29T23:29:03.788Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: TB 500 for Tirzepatide\nSlug: tb-500-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tb-500\",\"name\":\"TB-500\"},{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tb-500\",\"name\":\"TB-500\",\"section_title\":\"Why TB-500 might help you\",\"layer\":\"inflammation clearance / repair-cell migration\",\"steps\":[\"**What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\",\"**What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\",\"**Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"},{\"pe","response":"{\n  \"slug\": \"tb-500-tirzepatide\",\n  \"title\": \"TB-500 and Tirzepatide: Layered Repair Pathways and Metabolic Load Evidence\",\n  \"body\": \"## What's breaking down\\n\\nNo single disease profile defines this cross. The slug points to someone already using Tirzepatide for metabolic control and weight change who is also exploring TB-500 for tissue repair questions. Degeneration layers that commonly appear in such discussions include stalled inflammation clearance after micro-injury, disorganized repair-cell migration to damage sites, and ongoing mechanical stress from higher body weight on spine and joints. Repair outruns degeneration when cells reach the site, clear debris, and rebuild matrix. When migration stalls or load stays high, the imbalance persists.\\n\\n## Why TB-500 might help you\\n\\n1. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\\n\\n## Why Tirzepatide might help you\\n\\n1. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\n## How these fit together\\n\\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\\n- TB-500 → inflammation clearance / repair-cell migration\\n- Tirzepatide → metabolic load / body weight\\n\\n## What the evidence actually shows\\n\\nHuman data on full-length thymosin beta-4 (TB4) in","tokens_in":15403,"tokens_out":3018,"cost":0,"prev":"genesis","hash":"91f626e30f8904ab038deff6f6cfae4aa255a9a83ab88c4b3ada679486eb443d"},{"ts":"2026-07-17T02:42:19.587Z","model":"owner","action":"voxel_divide","prompt":"","input":"tb-500-tirzepatide","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"91f626e30f8904ab038deff6f6cfae4aa255a9a83ab88c4b3ada679486eb443d","hash":"515fc0c0a50d4947610dc6d5e9dab947025407c2e7054278f383c7aaddb10b46"}],"energy":{"passes":2,"tokens_in":15403,"tokens_out":3018,"tokens_total":18421,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"515fc0c0a50d4947610dc6d5e9dab947025407c2e7054278f383c7aaddb10b46"},"posted_at":"2026-06-29T21:33:30.418Z","created_at":"2026-06-29T21:33:30.418Z","updated_at":"2026-07-17T02:42:19.587Z","machine":{"shape":"article.machine/v1","slug":"tb-500-tirzepatide","kind":"article","read":{"human":"https://miscsubjects.com/a/tb-500-tirzepatide","json":"https://miscsubjects.com/api/articles/tb-500-tirzepatide","bundle":"https://miscsubjects.com/api/articles/tb-500-tirzepatide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tb-500-tirzepatide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tb-500-tirzepatide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-tirzepatide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-tirzepatide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tb-500-tirzepatide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tb-500-tirzepatide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tb-500-tirzepatide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tb-500-tirzepatide","json":"/api/articles/tb-500-tirzepatide","markdown":"/api/articles/tb-500-tirzepatide/bundle?format=markdown","skill":"/api/articles/tb-500-tirzepatide/skill","topology":"/api/articles/tb-500-tirzepatide/topology","versions":"/api/articles/tb-500-tirzepatide/revisions","invocations":"/api/articles/tb-500-tirzepatide/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tb-500-tirzepatide","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"9575e51fef8067f84e9cfd2bc022819cf72e5cf1ae83cfe51b2d994c1ed731be","object":{"object_type":"article-object","identity":{"id":"article:tb-500-tirzepatide","slug":"tb-500-tirzepatide","title":"TB-500 and Tirzepatide: Layered Repair Pathways and Metabolic Load Evidence"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tb-500-tirzepatide","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tb-500-tirzepatide/skill","role":"direct behavior","audience":"model","content":"---\nname: tb-500-tirzepatide\ndescription: Apply the TB-500 and Tirzepatide: Layered Repair Pathways and Metabolic Load Evidence article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# TB-500 and Tirzepatide: Layered Repair Pathways and Metabolic Load Evidence\n\nThis Skill is the behavioral expression of [the canonical article](/a/tb-500-tirzepatide). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tb-500-tirzepatide.\n- Read claims and relationships at /api/articles/tb-500-tirzepatide/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down No single disease profile defines this cross. The slug points to someone already using Tirzepatide for metabolic control and weight change who is also exploring TB-500 for tissue repair questions. Degeneration layers th\n\n## Representations\n\n- Human: /a/tb-500-tirzepatide\n- JSON: /api/articles/tb-500-tirzepatide\n- Relationships: /api/articles/tb-500-tirzepatide/topology\n- History: /api/articles/tb-500-tirzepatide/revisions\n"},"json":{"route":"/api/articles/tb-500-tirzepatide","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tb-500-tirzepatide/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","tb","500","tirzepatide"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tb-500-tirzepatide/invocations?status=success","failure_events":"/api/articles/tb-500-tirzepatide/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tb-500-tirzepatide","title":"TB-500 and Tirzepatide: Layered Repair Pathways and Metabolic Load Evidence","body":"## What's breaking down\n\nNo single disease profile defines this cross. The slug points to someone already using Tirzepatide for metabolic control and weight change who is also exploring TB-500 for tissue repair questions. Degeneration layers that commonly appear in such discussions include stalled inflammation clearance after micro-injury, disorganized repair-cell migration to damage sites, and ongoing mechanical stress from higher body weight on spine and joints. Repair outruns degeneration when cells reach the site, clear debris, and rebuild matrix. When migration stalls or load stays high, the imbalance persists.\n\n## Why TB-500 might help you\n\n1. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n2. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n3. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\n2. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\n3. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- TB-500 → inflammation clearance / repair-cell migration\n- Tirzepatide → metabolic load / body weight\n\n## What the evidence actually shows\n\nHuman data on full-length thymosin beta-4 (TB4) includes small trials for cardiac repair after heart attack and for eye surface healing. One 2016 pilot in STEMI patients suggested feasibility and safety for TB4-optimized cell therapy. Separate eye trials showed reduced dryness and discomfort. Wound healing trials reported faster closure in certain chronic ulcers. TB-500 itself, the fragment, lacks dedicated large human trials; most support remains preclinical or mechanistic.\n\nTirzepatide human trials (SURMOUNT series) show 15-21% average body weight reduction over 72 weeks in obesity cohorts. Weight loss of this magnitude reduces compressive force on lumbar discs and joints. Tirzepatide data is human and large-scale.\n\nPreclinical work on TB4/TB-500 centers on actin sequestration, angiogenesis, and reduced fibrosis in rat and mouse injury models. Rat wound and cardiac studies demonstrate cell migration and matrix remodeling. No large human randomized controlled trials exist for TB-500 specifically.\n\nAnecdotal reports on forums describe users pairing TB-500 with recovery goals while on GLP-1 agents, but these remain individual accounts without controlled measurement.\n\n## What scientists say\n\nReviews note TB4's role in embryonic-like repair programs in adult tissues, with early human signals in heart and eye but call for more controlled data. Tirzepatide researchers emphasize sustained weight reduction and metabolic improvement in published trial results. No peer-reviewed papers directly examine the TB-500 plus Tirzepatide pairing.\n\n## What people say on Reddit\n\nForum threads mention TB-500 alongside recovery stacks and occasionally list Tirzepatide in broader peptide regimens for long-term users. Discussions focus on perceived tissue support during weight change rather than combined mechanisms. Logs are personal and vary in detail.\n\n## What people say on X\n\nPosts referencing both compounds are sparse and mostly promotional or speculative. Few verified user reports tie specific outcomes to the combination.\n\n## What we do not know\n\nNo human trials test TB-500 during Tirzepatide treatment. Long-term effects on joint loading after major weight loss combined with repair peptides remain unstudied. Individual responses to either compound vary widely.\n\n## Safety and limits\n\nTirzepatide carries documented gastrointestinal side effects in trials. TB-500 and TB4 show favorable short-term safety signals in the limited human data available, yet regulatory status for research peptides limits clinical oversight. Evidence grading stays separate: human trial data for Tirzepatide weight effects, smaller human signals plus mostly preclinical for TB4/TB-500, and anecdotal for stacks.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tb-500-tirzepatide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Human trials of full-length TB4 showed reduced eye dryness and faster wound closure in small studies.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Separates human data from preclinical for TB-500 discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Tirzepatide produced 15-21% mean weight loss over 72 weeks in SURMOUNT obesity trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides quantified human metabolic load reduction data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"TB-500 fragment lacks large dedicated human trials; support is mainly preclinical.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Maintains evidence tier separation.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users discuss TB-500 in recovery stacks sometimes listed with Tirzepatide.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents forum-level reports without claiming efficacy.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://www.innerbody.com/thymosin-beta-4-and-tb-500","title":"TB4 and TB-500 Peptide Therapy | What to Know in 2026","quote":"A 2021 review covers the results of a few human TB4 trials... eye health... wound healing both resulted in the peptide accelerating the healing process.","summary":"Summarizes limited human TB4 trial signals in eye and wound contexts.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:29:03.186Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"bf21d43aaf96337a9138ad74f5402b928b16e118dd3ae5f73e447b695a7d42d5"},{"id":"s2","type":"clinical_trial","url":"https://www.prnewswire.com/news-releases/tirzepatide-demonstrated-significant-and-superior-weight-loss-compared-to-placebo-in-two-pivotal-studies-301887287.html","title":"Tirzepatide demonstrated significant and superior weight loss","quote":"Participants in SURMOUNT-3... additional 21.1% mean weight loss","summary":"Reports quantified weight loss from pivotal human trials.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:29:03.186Z","link_status":"ok","quote_status":"unverified","prev":"bf21d43aaf96337a9138ad74f5402b928b16e118dd3ae5f73e447b695a7d42d5","hash":"40a66d44e5efba6bfa83fd1a25008220cbb9a9f8f5c647e8b84bfcfe597eb6e1"},{"id":"s3","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing","quote":"We conducted a scoping review to map the evidence on TB4 and TB-500 in tissue healing, regeneration, and musculoskeletal repair.","summary":"Highlights predominantly preclinical evidence base.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:29:03.186Z","link_status":"http_403","quote_status":"unverified","prev":"40a66d44e5efba6bfa83fd1a25008220cbb9a9f8f5c647e8b84bfcfe597eb6e1","hash":"2c2d152f2124fe3314e4713ac4f6396ef2b181f98c89d0abe958a6182fe8815b"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/NTNPerformance/comments/1tc5a9d/peptide_stacking_cheat_sheet_what_goes_together/","title":"Peptide stacking cheat sheet","quote":"BPC-157 + TB-500 The wolverine stack... Tirzepatide + CJC/Ipamorelin","summary":"Captures forum discussion of peptide combinations including Tirzepatide context.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:29:03.186Z","link_status":"ok","quote_status":"unverified","prev":"2c2d152f2124fe3314e4713ac4f6396ef2b181f98c89d0abe958a6182fe8815b","hash":"3ed56389b2b16c31af8a53188a083addd46c7c258beb674a366d6778ed2f3934"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:29:03.788Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"TB-500 and Tirzepatide: Layered Repair Pathways and Metabolic Load Evidence","register":"source_ledger","body":"## What's breaking down\n\nNo single disease profile defines this cross. The slug points to someone already using Tirzepatide for metabolic control and weight change who is also exploring TB-500 for tissue repair questions. Degeneration layers that commonly appear in such discussions include stalled inflammation clearance after micro-injury, disorganized repair-cell migration to damage sites, and ongoing mechanical stress from higher body weight on spine and joints. Repair outruns degeneration when cells reach the site, clear debris, and rebuild matrix. When migration stalls or load stays high, the imbalance persists.\n\n## Why TB-500 might help you\n\n1. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n2. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n3. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\n2. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\n3. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- TB-500 → inflammation clearance / repair-cell migration\n- Tirzepatide → metabolic load / body weight\n\n## What the evidence actually shows\n\nHuman data on full-length thymosin beta-4 (TB4) includes small trials for cardiac repair after heart attack and for eye surface healing. One 2016 pilot in STEMI patients suggested feasibility and safety for TB4-optimized cell therapy. Separate eye trials showed reduced dryness and discomfort. Wound healing trials reported faster closure in certain chronic ulcers. TB-500 itself, the fragment, lacks dedicated large human trials; most support remains preclinical or mechanistic.\n\nTirzepatide human trials (SURMOUNT series) show 15-21% average body weight reduction over 72 weeks in obesity cohorts. Weight loss of this magnitude reduces compressive force on lumbar discs and joints. Tirzepatide data is human and large-scale.\n\nPreclinical work on TB4/TB-500 centers on actin sequestration, angiogenesis, and reduced fibrosis in rat and mouse injury models. Rat wound and cardiac studies demonstrate cell migration and matrix remodeling. No large human randomized controlled trials exist for TB-500 specifically.\n\nAnecdotal reports on forums describe users pairing TB-500 with recovery goals while on GLP-1 agents, but these remain individual accounts without controlled measurement.\n\n## What scientists say\n\nReviews note TB4's role in embryonic-like repair programs in adult tissues, with early human signals in heart and eye but call for more controlled data. Tirzepatide researchers emphasize sustained weight reduction and metabolic improvement in published trial results. No peer-reviewed papers directly examine the TB-500 plus Tirzepatide pairing.\n\n## What people say on Reddit\n\nForum threads mention TB-500 alongside recovery stacks and occasionally list Tirzepatide in broader peptide regimens for long-term users. Discussions focus on perceived tissue support during weight change rather than combined mechanisms. Logs are personal and vary in detail.\n\n## What people say on X\n\nPosts referencing both compounds are sparse and mostly promotional or speculative. Few verified user reports tie specific outcomes to the combination.\n\n## What we do not know\n\nNo human trials test TB-500 during Tirzepatide treatment. Long-term effects on joint loading after major weight loss combined with repair peptides remain unstudied. Individual responses to either compound vary widely.\n\n## Safety and limits\n\nTirzepatide carries documented gastrointestinal side effects in trials. TB-500 and TB4 show favorable short-term safety signals in the limited human data available, yet regulatory status for research peptides limits clinical oversight. Evidence grading stays separate: human trial data for Tirzepatide weight effects, smaller human signals plus mostly preclinical for TB4/TB-500, and anecdotal for stacks.","claims":[{"id":"c1","text":"Human trials of full-length TB4 showed reduced eye dryness and faster wound closure in small studies.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Separates human data from preclinical for TB-500 discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Tirzepatide produced 15-21% mean weight loss over 72 weeks in SURMOUNT obesity trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides quantified human metabolic load reduction data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"TB-500 fragment lacks large dedicated human trials; support is mainly preclinical.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Maintains evidence tier separation.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users discuss TB-500 in recovery stacks sometimes listed with Tirzepatide.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents forum-level reports without claiming efficacy.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:29:03.313Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://www.innerbody.com/thymosin-beta-4-and-tb-500","title":"TB4 and TB-500 Peptide Therapy | What to Know in 2026","quote":"A 2021 review covers the results of a few human TB4 trials... eye health... wound healing both resulted in the peptide accelerating the healing process.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"clinical_trial","url":"https://www.prnewswire.com/news-releases/tirzepatide-demonstrated-significant-and-superior-weight-loss-compared-to-placebo-in-two-pivotal-studies-301887287.html","title":"Tirzepatide demonstrated significant and superior weight loss","quote":"Participants in SURMOUNT-3... additional 21.1% mean weight loss","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing","quote":"We conducted a scoping review to map the evidence on TB4 and TB-500 in tissue healing, regeneration, and musculoskeletal repair.","link_status":"http_403","quote_status":"unverified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/NTNPerformance/comments/1tc5a9d/peptide_stacking_cheat_sheet_what_goes_together/","title":"Peptide stacking cheat sheet","quote":"BPC-157 + TB-500 The wolverine stack... Tirzepatide + CJC/Ipamorelin","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":15403,"tokens_out":3018,"cost":0.02679875,"prev_hash":"genesis","hash":"81a855ee4fb84d77b63987384a745b4535db3c6bf6002a5467174bdb1f2e60e3"}],"provenance":[{"ts":"2026-06-29T23:29:03.788Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: TB 500 for Tirzepatide\nSlug: tb-500-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tb-500\",\"name\":\"TB-500\"},{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tb-500\",\"name\":\"TB-500\",\"section_title\":\"Why TB-500 might help you\",\"layer\":\"inflammation clearance / repair-cell migration\",\"steps\":[\"**What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\",\"**What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\",\"**Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"},{\"pe","response":"{\n  \"slug\": \"tb-500-tirzepatide\",\n  \"title\": \"TB-500 and Tirzepatide: Layered Repair Pathways and Metabolic Load Evidence\",\n  \"body\": \"## What's breaking down\\n\\nNo single disease profile defines this cross. The slug points to someone already using Tirzepatide for metabolic control and weight change who is also exploring TB-500 for tissue repair questions. Degeneration layers that commonly appear in such discussions include stalled inflammation clearance after micro-injury, disorganized repair-cell migration to damage sites, and ongoing mechanical stress from higher body weight on spine and joints. Repair outruns degeneration when cells reach the site, clear debris, and rebuild matrix. When migration stalls or load stays high, the imbalance persists.\\n\\n## Why TB-500 might help you\\n\\n1. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\\n\\n## Why Tirzepatide might help you\\n\\n1. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\n## How these fit together\\n\\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\\n- TB-500 → inflammation clearance / repair-cell migration\\n- Tirzepatide → metabolic load / body weight\\n\\n## What the evidence actually shows\\n\\nHuman data on full-length thymosin beta-4 (TB4) in","tokens_in":15403,"tokens_out":3018,"cost":0,"prev":"genesis","hash":"91f626e30f8904ab038deff6f6cfae4aa255a9a83ab88c4b3ada679486eb443d"},{"ts":"2026-07-17T02:42:19.587Z","model":"owner","action":"voxel_divide","prompt":"","input":"tb-500-tirzepatide","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"91f626e30f8904ab038deff6f6cfae4aa255a9a83ab88c4b3ada679486eb443d","hash":"515fc0c0a50d4947610dc6d5e9dab947025407c2e7054278f383c7aaddb10b46"}],"energy":{"passes":2,"tokens_in":15403,"tokens_out":3018,"tokens_total":18421,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"515fc0c0a50d4947610dc6d5e9dab947025407c2e7054278f383c7aaddb10b46"},"posted_at":"2026-06-29T21:33:30.418Z","created_at":"2026-06-29T21:33:30.418Z","updated_at":"2026-07-17T02:42:19.587Z","machine":{"shape":"article.machine/v1","slug":"tb-500-tirzepatide","kind":"article","read":{"human":"https://miscsubjects.com/a/tb-500-tirzepatide","json":"https://miscsubjects.com/api/articles/tb-500-tirzepatide","bundle":"https://miscsubjects.com/api/articles/tb-500-tirzepatide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tb-500-tirzepatide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tb-500-tirzepatide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-tirzepatide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-tirzepatide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tb-500-tirzepatide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tb-500-tirzepatide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tb-500-tirzepatide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tb-500-tirzepatide","json":"/api/articles/tb-500-tirzepatide","markdown":"/api/articles/tb-500-tirzepatide/bundle?format=markdown","skill":"/api/articles/tb-500-tirzepatide/skill","topology":"/api/articles/tb-500-tirzepatide/topology","versions":"/api/articles/tb-500-tirzepatide/revisions","invocations":"/api/articles/tb-500-tirzepatide/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tb-500-tirzepatide","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"9575e51fef8067f84e9cfd2bc022819cf72e5cf1ae83cfe51b2d994c1ed731be"}}}